Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped If \</= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated.

Conditions

Leukemia

Interventions

DRUG: Gemcitabine Hydrochloride
DRUG: Mitoxantrone Hydrochloride

Sponsor

The Cleveland Clinic

Collaborators

[object Object]
[object Object]